Welcome to our dedicated page for Icad SEC filings (Ticker: ICAD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to historical SEC filings for iCAD, Inc. (formerly NASDAQ: ICAD), which operated as a public company focused on clinically proven AI-powered breast health and cancer detection solutions. These documents trace iCAD’s regulatory and financial reporting history up to its acquisition by RadNet, Inc., after which iCAD became a wholly owned subsidiary and its common stock registration was terminated.
Among the key filings are annual reports on Form 10-K and quarterly reports on Form 10-Q, which detail iCAD’s business description, risk factors, discussion of operations, and financial statements during its period as an independent issuer. Current reports on Form 8-K capture material events, including the July 14, 2025 special meeting at which stockholders approved the Agreement and Plan of Merger with RadNet and Trio Merger Sub, Inc. A Form 15 filed on July 28, 2025 certifies the termination of registration of iCAD’s common stock under Section 12(g) of the Exchange Act and the suspension of its duty to file further periodic reports.
Investors and researchers can also review proxy materials related to the merger, as referenced in company communications, to understand the terms of the transaction and the stockholder vote. Together, these filings document iCAD’s transition from a Nasdaq-listed company with the ICAD ticker to a wholly owned subsidiary within RadNet’s broader diagnostic imaging and digital health business.
On Stock Titan, users can quickly locate iCAD’s historical Forms 10-K, 10-Q, 8-K, and Form 15, and see how the company described its AI-powered ProFound Breast Health Suite, its revenue mix, and its shift toward recurring, cloud-based offerings over time. The filings page is useful for anyone analyzing the company’s legacy financial profile, governance history, and the regulatory steps surrounding its merger and deregistration.
THE GOLDMAN SACHS GROUP, INC. and Goldman Sachs & Co. LLC filed a Schedule 13G disclosing beneficial ownership of 1,452,580 shares of ICAD, Inc. common stock, representing 5.3% of the class. The filing shows shared voting and shared dispositive power over those shares and reports sole voting and dispositive power as 0. The statement affirms the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. A joint filing agreement and an exhibit identify Goldman Sachs & Co. LLC as a subsidiary and as a broker-dealer and registered investment adviser.